Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2020-10-09 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
S-8 Filing
Regulatory Filings
2020-10-09 English
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
Earnings Release Classification · 95% confidence The document is a press release from Galapagos NV, dated September 29, 2020, announcing the first patient dosing in a clinical study for their compound GLPG3970 in psoriasis. It details ongoing and planned clinical trials (CALOSOMA, SEA TURTLE, LADYBUG) and includes forward-looking statements typical of corporate news releases regarding drug development. This content structure—announcing clinical progress, trial details, and future investor events (Roundtable)—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it focuses on operational/clinical milestones rather than comprehensive financial results (which would suggest an IR or 10-K), and it is a formal announcement of results/progress, the most fitting category is Earnings Release (ER), as these often accompany or precede formal financial reports to highlight operational achievements. Alternatively, given the focus on clinical trial initiation and updates, it could be seen as a specific type of Investor Presentation (IP) material, but the format is clearly a press release. It is not a full financial report (10-K or IR), nor is it a simple announcement of a report publication (RPA). Therefore, ER is the best fit for a press release detailing operational/clinical progress. Q3 2020
2020-09-30 English
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
Regulatory Filings Classification · 95% confidence The document is a press release dated September 29, 2020, announcing the first dosing of a compound (GLPG3970) in a clinical trial for psoriasis. It details the initiation of patient trials for psoriasis, ulcerative colitis, and rheumatoid arthritis, and mentions an upcoming 'Toledo Roundtable' event. This content is characteristic of an announcement providing key operational and clinical development updates, often released outside of mandatory periodic filings like 10-K or IR. It is not a full financial report (10-K or IR), a transcript (CT), or a formal dividend/share change notice. Since it is a specific operational announcement about clinical progress and future investor events, it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but as a press release detailing clinical progress, RNS is the most appropriate general category for non-standard, material announcements, or ER if it were focused purely on financial results. Given the focus on clinical trial initiation and pipeline progress, RNS serves as the best fit among the provided options for a material corporate update that isn't a formal financial report or a specific management/governance filing.
2020-09-30 English
6-K Filing
Regulatory Filings
2020-09-30 English
EUROPESE COMMISSIE VERLEENT HANDELSVERGUNNING VOOR JYSELECA® (FILGOTINIB) VOOR DE BEHANDELING VAN VOLWASSENEN MET MATIGE TOT ERNSTIGE REUMATOïDE ARTRITIS
Regulatory Filings Classification · 100% confidence The document is a press release dated September 25, 2020, announcing that the European Commission (EC) has granted a marketing authorization for Jyseleca® (filgotinib) for the treatment of rheumatoid arthritis. It details clinical trial results (FINCH and DARWIN programs), safety profiles, and includes forward-looking statements typical of corporate news releases regarding regulatory milestones and future commercialization. This type of announcement, which communicates a significant regulatory event (drug approval) and provides key supporting data, is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific corporate event announcement that doesn't fit the other categories well (it's not a formal 10-K, AR, or a simple DIV/CAP announcement), it falls under the general category for significant corporate news that isn't a transcript or a formal report announcement. However, given the context of financial reporting, major corporate news releases announcing significant events like drug approvals or major partnerships often align closely with Earnings Releases (ER) in terms of immediate market impact and structure, or sometimes fall into Regulatory Filings (RNS) if they are purely informational disclosures. Since this is a detailed announcement of a major regulatory achievement and includes financial details (milestone payment), it functions as a high-impact corporate update. Given the options, and recognizing it is not a formal financial report (10-K, IR) or a simple announcement of a report (RPA), it most closely resembles an Earnings Release (ER) in its function as a primary results communication, or RNS as a general regulatory announcement. Since it is a specific, positive corporate development announcement, and not a standard quarterly earnings report, RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback for a major, non-standard corporate event disclosure that isn't explicitly covered elsewhere.
2020-09-28 Dutch
EUROPESE COMMISSIE VERLEENT HANDELSVERGUNNING VOOR JYSELECA® (FILGOTINIB) VOOR DE BEHANDELING VAN VOLWASSENEN MET MATIGE TOT ERNSTIGE REUMATOïDE ARTRITIS
Regulatory Filings Classification · 100% confidence The document is a press release dated September 25, 2020, announcing that the European Commission granted marketing authorization for Jyseleca® (filgotinib) for Rheumatoid Arthritis. It details the clinical trial data (FINCH and DARWIN programs) supporting this approval and includes forward-looking statements typical of corporate news releases regarding regulatory milestones and future commercialization. This type of announcement, which communicates a significant regulatory event (marketing authorization) and provides substantial clinical/business context, is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific regulatory/product approval announcement that doesn't fit other categories like M&A (TAR) or Capital Change (CAP), it falls under the general category for significant corporate news that isn't a formal statutory filing like 10-K or IR. However, given the options, this is a major corporate announcement regarding a product milestone. It is not a Call Transcript (CT), a formal Annual Report (10-K), or a simple Dividend Notice (DIV). It is a detailed announcement of a regulatory success, which often accompanies or precedes an Earnings Release, but here it stands alone as a major corporate event update. Since it is a detailed announcement of a major business/regulatory event, and not a short notice of a report being published (RPA/RNS), it is most closely aligned with an Earnings Release (ER) in terms of structure and purpose (announcing key performance/regulatory news), or potentially a Regulatory Filing (RNS) if it were less detailed. Given the depth of clinical data and executive commentary, it functions as a major corporate update, which often overlaps with ER content, but since it is specifically about a regulatory approval, it is a significant corporate announcement. In the absence of a specific 'Regulatory Approval Announcement' code, and noting it is not a formal statutory report, it is best categorized as a general Regulatory Filing (RNS) or an Earnings Release (ER) if it were tied to a period. Since it is a specific, non-periodic regulatory event announcement, RNS is the most appropriate fallback for significant, non-standard filings/announcements.
2020-09-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.